Cost-Effectiveness of Dronedarone in Atrial Fibrillation: Results for Canada, Italy, Sweden, and Switzerland

Clinical Therapeutics

Volumn 34, Issue 8, 2012, Pages 1788-1802

  Åkerborg, Örjan ^a   Nilsson, Jonas ^a   Bascle, Stephanie ^b   Lindgren, Peter ^a,c   Reynolds, Matthew ^d  

^a OptumInsight   (Sweden)

^b SANOFI   (France)

^c KAROLINSKA INSTITUTE   (Sweden)

^d HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Atrial fibrillation; Cost effectiveness; Health economic model; Simulation

Indexed keywords

CORTICOSTEROID; DRONEDARONE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DIARRHEA; DRUG COST; DRUG ERUPTION; DRUG UTILIZATION; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHOTOSENSITIVITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; STROKE; SURVIVAL; SURVIVAL TIME; SWEDEN; SWITZERLAND; TREATMENT WITHDRAWAL; VOMITING;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CANADA; COMPUTER SIMULATION; COST SAVINGS; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; DRUG COSTS; EUROPE; FEMALE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; MALE; MODELS, ECONOMIC; OFFICE VISITS; QUALITY-ADJUSTED LIFE YEARS; STROKE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864620961     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.06.007     Document Type: Article

References (43)

1. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998, 82:2N-9N.
2. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98:946-952.
3. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. 2010 2006, National Collaborating Centre for Chronic Conditions, Royal College of Physicians, London.
4. Wegener F.T., Ehrlich J.R., Hohnloser S.H. Dronedarone: an emerging agent with rhythm- and rate-controlling effects. J Cardiovasc Electrophysiol 2006, 17(Suppl 2):S17-S20.
5. Hohnloser S.H., Crijns H.J., van E.M., et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009, 360:668-678.
6. European Medicines Agency recommends restricting use of Multaq Accessed September 22, 2011. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/09/news_detail_001344.jsp&mid=WC0b01ac058004d5c1&jsenabled=true.
7. Ringborg A., Nieuwlaat R., Lindgren P., et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 2008, 10:403-411.
8. Holstenson E., Ringborg A., Lindgren P., et al. Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries. Europace 2011, 13:23-30.
9. Rabe-Hesketh S., Skrondal A. Multilevel and Longitudinal Modeling Using Stata 2005, Stata Press, College Station, TX.
10. Briggs A., Campbell H., Clarke P., Sculpher M. Parametric survival models and decision models: relating continuous hazards to discrete-time transition probabilities. Paper presented at the Health Economists' Study Group Conference 2004.
11. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
12. Feigin V.L., Lawes C.M., Bennett D.A., et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009, 8:355-369.
13. Lekander I., Borgstrom F., Strom O., et al. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial. Bone 2008, 42:294-306.
14. Shafazand M., Schaufelberger M., Lappas G., et al. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. Eur Heart J 2009, 30:671-678.
15. Mortality from Eurostat Accessed January 1, 2007. http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home.
16. Statistics Canada. CANSIM, Accessed May 19, 2009. http://cansim2.statcan.ca/.
17. OANDA - Forex trading and exchange rates services Accessed May 2, 2010. http://www.oanda.com.
18. European public assessment report (EPAR) for Multaq Accessed February 17, 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001043/human_med_001207.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125&jsenabled=true.
19. Multaq prescribing information Accessed February 2, 2012. http://products.sanofi.us/multaq/multaq.html.
20. Berg J., Lindgren P., Nieuwlaat R., et al. Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual Life Res 2010, 19:381-390.
21. Teng J. Cost and caregiver consequences of early supported discharge for stroke patients. Stroke 2003, 34:528-536.
22. Frasure-Smith N. Depression and health-care cost during the first year following a myocardial infarction. J Psychosom Res 2000, 48:471-478.
23. National Institute for Health and Clinical Excellence. The Guidelines Manual 2007.
24. Nathoe H.M., van D.D., Jansen E.W., et al. A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med 2003, 348:394-402.
25. Lonning P.E. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 2006, 17:217-225.
26. van Eijsden M.D., Gerhards S.A., de Bie R.A., Severens J.L. Cost-effectiveness of postural exercise therapy versus physiotherapy in computer screen-workers with early non-specific work-related upper limb disorders (WRULD); a randomized controlled trial. Trials 2009, 10:103.
27. Marshall D.A., Levy A.R., Vidaillet H., et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med 2004, 141:653-661.
28. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834-1840.
29. Catherwood E., Fitzpatrick W.D., Greenberg M.L., et al. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med 1999, 130:625-636.
30. Eckman M.H., Falk R.H., Pauker S.G. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med 1998, 158:1669-1677.
31. The Cost of Hospital Stay: Why Cost Vary. Ottawa, Canada 2008, Canadian Institute for Health Information (CIHI).
32. Rudelli G., Annemans L., Spiesser J., et al. An economic evaluation of clopidogrel vs. aspirin in secondary prevention of ischemic events in high risk atherothrombotic patients in Italy. Value Health 2004, 7:686-687.
33. Södra regionvårdsnämnden, priser NordDRG fullversion (sluten vård inkl kortvård), Accessed May 2, 2010. http://www.skane.se/upload/Webbplatser/Sodra%20regionvardsnamnden/prislista/2009/20_34_norddrg_fullversion09.pdf.
34. Södra regionvårdsnämnden, priser NordDRG classic, Accessed May 2, 2010. http://www.skane.se/upload/Webbplatser/Sodra%20regionvardsnamnden/prislista/2009/35_45_norddrg_halland09.pdf.
35. Priser och ersättningar för sydöstra sjukvårdsregionen 2009, Accessed May 2, 2010. http://www.sydostrasjukvardsregionen.se/Filer/Annas-mapp/RSN/Arkiv/Bilagor/20081209Arende9RSN.pdf.
36. Utomlänspriser 2009 för vårdtjänster enligt samverkansavtal om hälso- och sjukvård inom Västra sjukvårdsregionen, Accessed May 2, 2010. http://www.vgregion.se/upload/svn%20-%20samverkansn%c3%a4mden/Utoml%c3%a4nsprislista%202009.pdf?epslanguage=sv.
37. Utomregionsprislistor år 2009 för Stockholm-Gotland regionen, Accessed May 2, 1010. http://extern.bkv.sll.se/samv.sthlm-gotland/Prislistor/2009/prislistor_2009.htm.
38. Regional prislista för Uppsala-Örebroregionen 2009, Accessed May 2, 2010. http://www.externt9.lul.se/svn/document/prislistor/2011/prislista11info.pdf.
39. Prislistor norra sjukvårdsregionen, Accessed May 2, 2010. http://www.norrlandstingen.se/lankar_prislistor.htm.
40. Ontario Case Costing Initiative 2008, Ontario Ministry of Health and Long-Term Care, Ontario, Canada.
41. Szucs T. Gesundheitsökonomische aspekte der chronischen herzinsuffizienz. Schweizeriche Ärztezeitung 2003, 84:2431-2435.
42. Krankenhausstatistik 2007 - Standardtabellen. Definitive Resulate. Neuchâtel 2009 Bundesamt für Statistik (BFS), Accessed May 2, 2010. http://www.health-stat.admin.
43. Cost-Weights et Swiss Payment Groups Version 6.0 APDRG Suisse, Accessed May 2, 2010. http://www.apdrgsuisse.ch.